Navigation Links
FDA Reviewer Questions Results of Key Avandia Trial

By Amanda Gardner
HealthDay Reporter

FRIDAY, July 9 (HealthDay News) -- One step ahead of a planned government review of the safety of Avandia, new doubts surfaced Friday on a key trial that helped keep the blockbuster diabetes drug on the market.

A medical reviewer for the U.S. Food and Drug Administration posted remarks on the agency's Web site Friday suggesting that drugmaker GlaxoSmithKline's "mishandling" of trial results may have masked some cardiovascular effects of Avandia (rosiglitazone).

The official's posting was part of a safety reassessment package prepared for next week's advisory panel meeting that could determine the future of the controversial drug.

At issue in the review posting were the results of the landmark RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes) trial, which was done by Glaxo at the FDA's request. The results, announced in June of 2009, found that Avandia raised the risk of heart failure but not to a level of statistical significance. The study also concluded that the drug did not increase the risk of cardiovascular disease or overall death.

In his posting, Thomas A. Marciniak, medical team leader of the division of cardiovascular and renal products at the FDA's Center for Drug Control and Evaluation, said that "RECORD was inadequately designed and conducted to provide any reassurance about the [cardiovascular] safety of rosiglitazone" and that "RECORD suggests the (sic) rosiglitazone increases the risk for [heart attacks]."

Last June, Glaxo used the trial results to tout the drug's safety.

"RECORD provides important and reassuring information about Avandia for physicians fighting diabetes," said Dr. Ellen Strahlman, Glaxo's chief medical officer, in a statement released at the time. "We believe that the results showed that Avandia is safe."

On Friday, the company, in a prepared statement, said, "The RECORD study was conducted according to good clinical practices and the data are reliable. . . RECORD demonstrated that Avandia was not associated with an overall increase in cardiovascular hospitalization or cardiovascular death compared to metformin and sulfonylureas."

But Dr. Kirk Garratt, clinical director of interventional cardiovascular research at Lenox Hill Hospital in New York City, said Friday, "If the data from RECORD had truly been mishandled in some way, not only is it going to pretty well be the end of Avandia in the clinical world, but it's going to put GlaxoSmithKline under the magnifying glass in an important way for clinicians going forward. They'll lose credibility, and that's tough to get back."

"There is an alternative drug out there," Garratt added. "From the clinical side, it's a fortunate circumstance that we find ourselves in, since we have an alternative product that seems to have [little] risk associated with it."

Actos (pioglitazone), made by Takeda, is in the same pharmaceutical class as Avandia. Both are medications known as thiazolidinediones (TZDs), which are blood-sugar-lowering drugs. Both are used by type 2 diabetics.

"The bulk of studies have suggested that Avandia is associated with greater cardiovascular mortality than the alternative, which is pioglitazone," noted Dr. Ronald Goldberg, a professor of medicine at the University of Miami Miller School of Medicine, on Friday.

This is only the latest in a series of conflicting information about Avandia's heart risks. In November of 2007, the FDA added a boxed warning to the drug, saying that there was a potential risk of increased cardiovascular ischemic events. Patients also began receiving a medication guide explaining the risks.

But just last week, three studies emerged with conflicting conclusions about the drug's safety. Two of them, published in major medical journals, found that Avandia did raise heart risks, while the third, released at the American Diabetes Association meeting, found no such connection.

Next week's meeting will shed much-needed light on the matter.

When the advisory panel meets Tuesday and Wednesday, its options "range from allowing the continued marketing of Avandia and revising the label to remove the boxed warning, all the way to withdrawal from the U.S. market," Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, explained at a packed news briefing late Thursday. "We're asking them to pick one, vote on it and explain the rationale."

But, according to the The New York Times, the panel will also be asked to decide whether a currrent Glaxo study comparing the safety of Avandia and Actos is ethical. The study is being done at the FDA's request.

The FDA is not bound to follow the recommendations of its advisory committees but usually does.

Much of the current controversy, Garratt said, "probably reflects dissent within FDA. They've been debating this internally for a long time. This is probably just turning up the heat on that argument."

Dr. Joshua Sharfstein, principal deputy commissioner of the FDA, told reporters on Thursday, "Obviously, we're going to have to look at a lot of information and really understand the advice that we're getting and try to make a decision as quickly as we can under the circumstances. This is an FDA decision."

Meanwhile, the European Medicines Agency announced Friday morning that it would also review Avandia's safety for use in Europe. The Associated Press reports that the review will be conducted by the agency's Committee for Medicinal Products for Human Use from July 19 to July 22.

More information

The U.S. National Library of Medicine has more on Avandia and Actos.

SOURCES: Kirk Garratt, M.D., clinical director of interventional cardiovascular research, Lenox Hill Hospital, New York City; Ronald Goldberg, M.D., professor of medicine, University of Miami Miller School of Medicine; July 9, 2010, statement, GlaxoSmithKline; July 8, 2010 teleconference with Janet Woodcock, M.D., director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration; Joshua Sharfstein, M.D., principal deputy commissioner, FDA, and Jill Warner, acting associate commissioner for Special Medical Programs, FDA; Associated Press; New York Times

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Readers and Reviewers Rave about 'The Skinny On Willpower'
2. Few High-Quality Studies on Food Allergies, Say Reviewers
3. Study Questions Value of Test for Peripheral Artery Disease
4. -- Food, Fiber and Fuel Questions Answered
5. National Event Addresses Breakthroughs in Crohn's & Colitis Research: National Expert & Researcher Answers Key Questions on Interactive Webcast/Teleconference
6. New study questions benefits of elective removal of ovaries during hysterectomy
7. Panel questions VBAC bans, advocates expanded delivery options for women
8. New Master Cleanse Website Offers Open Q&A For Master Cleanse Diet Questions
9. New iVillage Study Reveals That Majority of Women 18-34 Go Online First With Health Questions - Before Turning to Their Doctor or Other Family Members
10. Live Online Chats Answer Questions About Vascular Disease
11. Study Questions Use of Heart Device Implants in the Very Old
Post Your Comments:
Related Image:
FDA Reviewer Questions Results of Key Avandia Trial
(Date:11/28/2015)... ... November 28, 2015 , ... StatRad , ... added Chris Hafey and Claude Hooton to its board of directors. The announcement ... America (RSNA) 2015 Annual Meeting and continues to strategically transform its focus from ...
(Date:11/28/2015)... ... November 28, 2015 , ... Beginning November 30th at 6:00 a.m. EST until 11:59 p.m. EST, ... With possible savings of up to 20% off orders $80 or more to free gifts ... every few hours. , As a competitive e-commerce website for skin care and cosmetic needs, ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published November ... meeting in Washington D.C. revolved around the fact that proper dental care, both at-home ... stressed the link between periodontal disease (more commonly referred to as gum disease) and ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... affecting the health care in America. As people age, more care is needed, ... costs are rising, and medical professionals are being overworked. The forgotten part of ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When ... said an inventor from Hillside, N.J. "Many people catch diseases simply from sitting ... individuals will always be protected from germs." , He developed the patent-pending QUDRATECS ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 3D bioprinting market ... to a new report by Grand View Research Inc. Rising ... which demands kidney transplantation is expected to boost the market ... for organ transplantation. --> 3D bioprinting market ... to a new report by Grand View Research Inc. Rising ...
(Date:11/26/2015)... November 26, 2015 ... universitetssjukhus ser potential att använda SyMRI för ... för patienter med multipel skleros (MS) ... med SyntheticMR AB för att kunna använda ... sjukhuset. Med SyMRI kan man generera flera ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Italian ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
Breaking Medicine Technology: